After Treatment Ends: What Cancer Surveillance Is Actually Looking For
Treatment ends and the calendar empties. No more infusions, no more weekly contact, just a follow-up date months away. The team that watched you every week now sees you twice a year. That gap is where the fear lives: across 46 studies covering 11,226 people, 58.8% scored at or above the moderate-fear threshold on the Fear of Cancer Recurrence Inventory and 19.2% scored at or above the high-fear threshold (Luigjes-Huizer et al., Psycho-Oncology 2022). Here is what changes how the next scan feels. Surveillance is a comparison, not a snapshot, so the value of every scan is the one before it, and holding that whole line in order is what Healz's memory does.
This post walks through what a surveillance plan is built from, why more imaging is not automatically safer, what a rising marker does and does not mean, and the part of follow-up that is not about recurrence. One point up front: there is no universal schedule. Guidelines are disease-specific and often stage-specific, and a plan that is right after colon cancer would be wrong after breast cancer.
Why the quiet after treatment is the hardest part
During treatment there is a plan for every week. After it, the plan is mostly waiting, and waiting has no visible activity to it. Many people read that as being dropped. It is not. Surveillance has a specific job: catch a recurrence or a second cancer at a point where treatment still changes the outcome, manage what the treatment left behind, and do both without generating so many false alarms that follow-up becomes its own illness.
That last clause is why the schedule can look thinner than you expected. A test earns its place because finding something with it earlier leads to a better outcome, not merely because it finds things.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
What a surveillance plan is actually built from
Nearly every plan is assembled from the same four parts, in proportions that depend on the cancer.
History and physical exam. The most consistent element across every guideline, and the most underrated: it is where you report the symptom that gets imaged.
Imaging, on a schedule or on a symptom. Some cancers get calendar imaging; many get imaged only when something is reported.
Tumor markers, where they have been validated for that disease. Validated is doing heavy work there, and the next section is about it.
Endoscopy or direct inspection, where the surface can be seen. Colonoscopy after colorectal cancer, skin checks after melanoma, laryngoscopy after head and neck cancer.
The same four parts, in three diseases. After curative treatment for colorectal cancer, NCCN advises exam and CEA every 3 to 6 months for two years then every 6 months out to five years, CT of the chest, abdomen, and pelvis at 6 to 12 month intervals for five years, and colonoscopy about one year after resection, repeated at three years and then every five years if it stays clean. After breast cancer, ASCO's 2026 update sets visit frequency by recurrence risk (roughly annual for low risk, every 6 to 12 months for intermediate, every 3 to 6 months for high) with mammography of any remaining breast tissue annually for the first three years and every one to two years after that for selected lower-risk patients aged 50 and over, and explicitly no routine CT, PET, bone scan, or tumor markers without symptoms. After head and neck cancer, NCCN concentrates visits early, every 1 to 3 months in year one, every 2 to 6 months in year two, every 4 to 8 months in years three to five, because that is when recurrence clusters.
Three cancers, three plans that barely resemble each other. If your schedule looks lighter than a neighbor's, the question is not whether you are being neglected. It is which cancer, which stage, which guideline.
Why more scans are not automatically better
Scanning more often should catch things sooner, and sooner should be better. The evidence is more careful. In lymphoma, the Lugano recommendations explicitly discourage routine surveillance scans after a complete remission, particularly in diffuse large B-cell lymphoma and Hodgkin lymphoma. In breast cancer, ASCO repeated the same position in 2026: no routine body imaging for distant metastases in asymptomatic patients. In colorectal cancer, the FACS randomized trial (JAMA 2014, 1,202 patients) found that intensive CEA or CT follow-up did increase the number of recurrences treated surgically with curative intent, but overall mortality did not differ significantly, and the authors concluded that any survival advantage was likely to be small.
Every scan has a false-positive rate, and a false positive in someone who has had cancer is not a minor inconvenience: it is a biopsy, a wait, and weeks of fear. Scans also find unrelated things that need chasing, which our guide on reading a PET/CT report walks through, including why "avid" is not a synonym for cancer.
And routine tests are often not what finds the recurrence anyway. In a Swedish cohort of 2,728 breast cancer patients (Sartor et al., Breast Cancer Research and Treatment, 2025), 95% of distant metastases were found because the patient presented with a symptom, not through planned surveillance, while 72% of second primary cancers in the contralateral breast were caught on scheduled mammography. Together they explain the design: keep the test that reliably catches something early, drop the ones that mostly catch what the person would have reported anyway, and make sure the person knows which symptoms not to sit on.
What a rising tumor marker does and does not mean
A marker is a monitoring tool inside a specific disease, not a general cancer detector, and it behaves differently in each one.
CEA rises in plenty of things that are not cancer, including smoking, cirrhosis and other liver disease, pancreatitis, inflammatory bowel disease, and chest infections, which is why reference ranges run higher for smokers. One value above the range is not a recurrence. What matters in colorectal follow-up is a confirmed, sustained rise, which is why a repeat test comes before a scan.
CA-125 after ovarian cancer is the sharpest example of why an earlier answer is not automatically a better one. In the MRC OV05/EORTC 55955 randomized trial (Lancet 2010), starting chemotherapy on a rising CA-125 alone, before any clinical sign of relapse, produced no survival benefit over waiting. It moved the treatment and its side effects earlier without moving the outcome.
PSA after prostate surgery sits at the other end. AUA defines biochemical recurrence after radical prostatectomy as a PSA of 0.2 ng/mL or higher with a confirmatory second value above 0.2 ng/mL, and that threshold triggers a real decision. One word, marker, covers tests with completely different jobs, and our guide on how to read tumor markers covers what each is validated for. The rule that holds everywhere: a number is read against your own previous numbers first, and against a reference range second.
The half of follow-up that is not about recurrence
Watching for cancer is one column of the plan. The other is what treatment left behind, and it runs on a longer clock. Anthracycline chemotherapy carries a documented risk of cardiotoxicity that can appear years after the last dose. Radiation raises the risk of second cancers in the treated field. Endocrine therapy affects bone density. Some regimens leave lasting neuropathy, fertility effects, or thyroid dysfunction. None of these are found by looking for the original tumor.
This is what a survivorship care plan is for. The Institute of Medicine's 2005 report "From Cancer Patient to Cancer Survivor: Lost in Transition" recommended that every patient finishing treatment receive a written treatment summary plus a plan covering surveillance, late effects, and who owns which part. Ask for one in writing. It tells the primary care doctor you will see for the next thirty years which drugs you had, at what cumulative dose, over which field, and what to watch for as a result.
How Healz reads your surveillance history
Surveillance is a slope problem, and slopes get lost between a hospital portal, a lab app, and a folder of PDFs. Healz is equipped with memory: it keeps every scan report, marker value, and pathology note you upload, tracks each line across all of them, and sets today's report against the one before it, so a change reads as a direction rather than a frightening number. That is the comparison the whole strategy depends on.
The rest of the case sits in the same chat. As an ai lab report reader and for ai ct scan analysis, Healz reads the imaging report and the bloodwork together, so a marker is weighed against the scan and the symptom rather than alone. Frontier AI works your case. Root-cause technology cross-checks it against more than a million rare cases and drills past the headline to what is driving a change. Everything in one place, one chat, not ten apps and four portals. And when you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.
Frequently asked questions
- How often should I have scans after cancer treatment?
There is no single answer, because the cancer and the stage set the schedule. Colorectal surveillance includes CT of the chest, abdomen, and pelvis at 6 to 12 month intervals for five years (NCCN), while ASCO recommends no routine body imaging for asymptomatic breast cancer survivors (2026 update). Ask which guideline your plan follows.
- Does a rising tumor marker mean the cancer is back?
Not by itself. CEA rises in smoking, liver disease, pancreatitis, and inflammatory bowel disease, so a confirmatory repeat comes before any scan. And a rise is not always a reason to act early: in the MRC OV05/EORTC 55955 trial (Lancet 2010), treating ovarian relapse on a rising CA-125 alone gave no survival benefit over waiting for clinical signs.
- Why won't my oncologist order more frequent scans?
Because for several cancers the evidence does not support it. Lugano recommendations discourage routine surveillance scans in lymphoma after complete remission, and ASCO advises against routine CT, PET, or bone scans in asymptomatic breast cancer survivors. More imaging brings false positives, biopsies, and incidental findings without a matching gain.
- What is a survivorship care plan?
A written summary of the treatment you received plus a forward plan covering the surveillance schedule, expected late effects, and who owns each part of your follow-up. The Institute of Medicine recommended one for every patient finishing treatment in its 2005 report. Ask your team for a copy, and give one to your primary care doctor.
Surveillance is not a series of verdicts. It is one long line, and almost every decision comes from the difference between two points on it, not from any single point. Which is why keeping every report in one place, in order, is not administration. It is the method.
Written by Healz Team · Filed under Health Insights